Physician profile
Maria O Lopez
NPI 1538139936
$4,385.65
in general payments reported to CMS, 2019-2025
36 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $817 · 2021: $1,002 · 2022: $817 · 2023: $463 · 2024: $179 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.21 | 2020-2025 | |
| Abbott Laboratories | $687.01 | 2019-2022 | |
| Lilly USA, LLC | $345.62 | 2019-2025 | Zepbound |
| Novo Nordisk INC | $314.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $260.51 | 2019-2024 | Farxiga |
| Amgen INC. | $240.78 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $182.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.87 | 2020-2023 | Xifaxan |
| Harmony Biosciences LLC | $132.82 | 2020 | |
| Exact Sciences Corporation | $128.59 | 2023-2024 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $122.67 | 2020-2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.02 | 2021-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $107.12 | 2019-2023 | |
| Janssen Biotech, INC. | $89.92 | 2022-2023 | Stelara, Simponi Aria, Remicade |
| Bayer Healthcare Pharmaceuticals INC. | $78.59 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $71.75 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $62.75 | 2022-2023 | Ocaliva |
| Idorsia Pharmaceuticals US INC | $57.75 | 2023 | Quviviq |
| Mylan Specialty L.P. | $57.24 | 2019-2021 | |
| Redhill Biopharma INC. | $53.42 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $52.12 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $34.70 | 2019 | |
| Eisai INC. | $32.90 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $32.42 | 2019-2020 | |
| Esperion Therapeutics, INC. | $30.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.59 | 2019 | |
| Shire North American Group INC | $26.22 | 2019 | |
| Radius Health, INC. | $26.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.93 | 2019 | |
| Cardiovascular Systems INC. | $18.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.29 | 2022 | |
| Dermira, INC. | $17.02 | 2020 | |
| Astellas Pharma US INC | $15.41 | 2019 | |
| Ibsa Pharma INC. | $14.68 | 2019 | |
| Glaxosmithkline, LLC. | $14.46 | 2025 | Trelegy Ellipta |
| Allergan, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.